Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: a retrospective study

Figures & data

Table 1 Comparison of general characteristics between group A and group B

Characteristics	Group A	Group B	χ^2/t	P-value
Total number of patients	56	42	–	–
Age,a years (range)	23.8±3.6 (12–46)	22.6±3.2 (13–49)	1.037*	0.381
Gender (male/female)	33/23	24/18	0.031	0.859
Tumor location			–	0.983#
Ulna	3	2
Fibula	5	3
Tibia	24	19
Femur	26	18
Maximum tumor diameter (cm)			0.817	0.366
>10	18	10
≤10	38	32
Enneking stage			0.595	0.441
IIA	35	23
IIB	21	19
Type of reconstruction			46.427	0.000
Tumor inactivation and bone re-implantation	31	0
Artificial prosthesis replacement	6	29
Artificial hip arthroplasty	9	5
Artificial knee arthroplasty	10	8

Notes:

a Data shown as mean ± standard deviation.

* t value;

# Fisher’s exact test.

Table 2 Comparison of the recurrence rate and metastasis rate between group A and group B

Recurrence and metastasis	Group A (%)	Group B (%)
Local recurrence	8 (14.3)	11 (26.2)
Metastasis	6 (10.7)	8 (19.0)
Local recurrence + metastasis	0 (0.0)	1 (2.4)

Note: χ²=5.419, P=0.020.

Figure 1 PFS for patients in group A and group B.

Abbreviation: PFS, progression-free survival.

Figure 2 OS for patients in group A and group B.

Abbreviation: OS, overall survival.

Table 3 Comparison of the occurrence of grades III and IV adverse reactions during chemotherapy of the two groups

Adverse reactions	Group A	Group B	χ^2	P-value
Hematologic toxicities	13	9	0.044	0.834
Leukopenia	8	3
Thrombocytopenia	5	6
Gastrointestinal tract reaction	5	4	–	1.000#
Hepatic and renal dysfunction	2	1	–	1.000#

Note:

# Fisher’s exact test.

Table 4 Comparison of the limb function between group A and group B

Limb function	Group A (%)	Group B (%)
E	27 (48.2)	15 (35.7)
G	20 (35.7)	13 (31.0)
F	7 (12.5)	7 (16.7)
P	2 (3.6)	7 (16.7)
E and G	47 (83.9)	28 (66.7)

Note: χ²=3.982, P=0.046.

Abbreviations: E, excellent; G, good; F, feasible; P, poor.